Welcome to our dedicated page for Shuttle Pharmaceuticals Holdings news (Ticker: $SHPH), a resource for investors and traders seeking the latest updates and insights on Shuttle Pharmaceuticals Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Shuttle Pharmaceuticals Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Shuttle Pharmaceuticals Holdings's position in the market.
Rhea-AI Summary
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) will present at the Planet MicroCap Showcase: VEGAS 2024 on May 1, 2024, providing updates on its Phase 2 Clinical Trial of Ropidoxuridine for glioblastoma treatment and Shuttle Diagnostics, Inc.'s plans for predictive biomarkers in prostate cancer. Dr. Anatoly Dritschilo will lead the presentation at 4:30pm PT, followed by 1x1 meetings with investors on May 2, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
-
Rhea-AI Summary
Shuttle Pharmaceuticals Holdings, Inc. announces CEO's participation in the Emerging Growth Conference to discuss plans for subsidiary Shuttle Diagnostics, Inc. and recent developments in predictive biomarkers for prostate cancer outcomes and theranostic applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.4%
Tags
-
Rhea-AI Summary
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) provided a corporate update, highlighting FDA approval for Phase 2 Clinical Trial of Ropidoxuridine for glioblastoma, creation of Shuttle Diagnostics, licensing agreements, exclusive intellectual property acquisitions, and a planned Rights Offering to raise $4.5 million. The company's cash balance was $5.5 million as of December 31, 2023. Recent presentations included participation in investor conferences and updates on radiation sensitizer portfolio and diagnostic subsidiary.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
Rhea-AI Summary
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) CEO to Present at Emerging Growth Conference on March 6, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
-
Rhea-AI Summary
Shuttle Pharmaceuticals Holdings, Inc. announces a Rights Offering to raise up to $4.5 million through the distribution of subscription rights, offering existing stockholders the opportunity to purchase Units consisting of common stock, warrants, and equity interest in Diagnostics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
-
Rhea-AI Summary
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) CEO, Dr. Anatoly Dritschilo, will participate in a fireside chat and one-on-one meetings with investors at the Lytham Partners 2024 Investor Select Conference. The company recently received FDA approval to proceed with the Phase II clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma. The webcasted fireside chat will take place on February 1, 2024, and the webcast will be available for replay. Management will also participate in virtual one-on-one meetings throughout the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
Rhea-AI Summary
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) has received the 'Safe to Proceed' letter from the FDA for its Phase II study of Ropidoxuridine as a radiation sensitizing agent for glioblastoma. The company is finalizing site enrollment and expects the 'first patient, first dose' in the coming months. Ropidoxuridine is the company's lead candidate for use in combination with radiation therapy to treat glioblastoma, a deadly brain malignancy with no known cure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.48%
Tags
-
Rhea-AI Summary
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) has submitted an Investigational New Drug (IND) application with the U.S. FDA for Ropidoxuridine, its lead radiation sensitizer candidate for treating brain tumors. The company aims to increase cancer cure rates, prolong patient survival, and improve quality of life.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) announced that its CEO, Dr. Anatoly Dritschilo, will participate in the Emerging Growth Conference on December 7, 2023. The company is focused on improving outcomes for cancer patients undergoing radiation therapy. Dr. Dritschilo will conduct a presentation and Q&A session during the conference, with a webcast link available on the company's website. One-on-one investor meetings will also be hosted after the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.88%
Tags
Rhea-AI Summary
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) provided a corporate update on its recent achievements, including positive feedback from the FDA on its Ropidoxuridine clinical trial design, an exclusive IP licensing agreement with Georgetown University for a predictive biomarker program, and progress in its HDAC inhibitor platform. The company also reported on its Q3 2023 operating expenses and cash balance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
Shuttle Pharmaceuticals Holdings, Inc.
Nasdaq:SHPH
SHPH Rankings
SHPH Stock Data
6.82M
9.55M
45.11%
2.12%
0.39%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
United States of America
GAITHERSBURG